Table 5.

Hypoglycaemic and hypolipidemic effects of A. vera in clinical studies.

Study type	Duration	Beneficial effects	Study population	Reference
Randomized controlled clinical trial	5 years	Decrease in TC, TG,LDL-C, FBG and postprandial blood glucose	5000 diabetics	[95]
Controlled clinical trial	84 days	Reduced TC by 15.4%, TG by 31.9% and, LDL by 18.2%	60 hyperlipidemic patients	[96]
Controlled clinical trial	42 days	Reduced FBG, triglycerides	72 diabetics	[97]
Controlled clinical trial	42 days	Reduced FBG, triglyceride levels	36 diabetics	[98]
Uncontrolled clinical trial	84 days	Decreased blood glucose and triglyceride levels. Improved HbA1c levels	15 diabetics	[99]
Double blind-placebo controlled clinical trial	61 days	Decrease in FBG and HbA1c	35 diabetics	[100]
Double blind-placebo controlled clinical trial	56 days	Decrease in FBG, HbA1c, TC, LDL-C	45 pre-diabetics	[101]
Placebo controlled clinical trial	90 days	Reduced FBG, TC, TG, VLDL, LDL-C, HbA1c, TC:HDL and increase in HDL-C	90 diabetics	[12]
Open label phase 1 trial	40 days	Decreased FBG, HbA1c, TC, LDL and triglycerides	30 diabetics	[105]
Randomized controlled trial	84 days	Decreased HbA1c, TC, LDL and triglycerides	50 diabetics	[106]
Randomized controlled trial	56 days	Reduced FBG, insulin resistance, body weight and body fat mass	136 pre-diabetics	[107]
Randomized-double blind placebo controlled clinical trial	61 days	Reduced FBG, HbA1c, TC and LDL levels	30 diabetics	[108]